• Host cell mTORC1 is required for HCV RNA replication.

      Stöhr, Stefanie; Costa, Rui; Sandmann, Lisa; Westhaus, Sandra; Pfaender, Stephanie; Anggakusuma; Dazert, Eva; Meuleman, Philip; Vondran, Florian W R; Manns, Michael P; et al. (2015-08-14)
      Chronically HCV-infected orthotopic liver transplantation (OLT) recipients appear to have improved outcomes when their immunosuppressive regimen includes a mammalian target of rapamycin (mTOR) inhibitor. The mechanism underlying this observation is unknown.
    • In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome.

      Todt, Daniel; Gisa, Anett; Radonic, Aleksandar; Nitsche, Andreas; Behrendt, Patrick; Suneetha, Pothakamuri Venkata; Pischke, Sven; Bremer, Birgit; Brown, Richard J P; Manns, Michael P; et al. (2016-10)
      Hepatitis E virus (HEV) infection can take chronic courses in immunocompromised patients potentially leading to liver cirrhosis and liver failure. Ribavirin (RBV) is currently the only treatment option for many patients, but treatment failure can occur which has been associated with the appearance of a distinct HEV polymerase mutant (G1634R). Here, we performed a detailed analysis of HEV viral intrahost evolution during chronic hepatitis E infections.